Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.350
-0.040 (-2.88%)
At close: Dec 5, 2025, 4:00 PM EST
1.369
+0.019 (1.42%)
After-hours: Dec 5, 2025, 7:59 PM EST
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
22.75M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
APVO News
- 25 days ago - Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors - Accesswire
- 4 weeks ago - Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update - Accesswire
- 2 months ago - Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter - Accesswire
- 2 months ago - Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML - Accesswire
- 3 months ago - Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules - Accesswire
- 4 months ago - Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - Accesswire
- 4 months ago - Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - Accesswire
- 6 months ago - Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire